Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-French health body approves AstraZeneca COVID-19 vaccine

Tue, 02nd Feb 2021 16:53

* Recommends use for those only aged under 65

* Decision makes AZ's vaccine third shot available in the
country
(Adds quote, details)

By Sudip Kar-Gupta and Geert De Clercq

PARIS, Feb 2 (Reuters) - France's top health advisory body
on Tuesday approved the use of AstraZeneca's COVID-19
vaccine, but said the shot should only be administered to those
aged under 65.

The Haute Autorite de la Sante (HAS) said people aged 50 to
65 with health issues and medical staff should get priority
access.

The decision makes AstraZeneca's vaccine the third shot
available in France, after those of Pfizer/BioNTech
and Moderna.

Its recommended use for those aged below 65 echoes similar
advice from experts in Italy, Austria, and Germany, which said
the vaccine should not be given to the elderly, citing a lack of
sufficient data to recommend use in older age groups.

"There is still insufficient data for those aged 65+. We
hope to have them in the coming weeks," the head of the HAS,
Dominique Le Guludec, told reporters.

"The vaccine's performance is satisfactory with a 62%-70%
efficacy depending on various study outcomes", she added.

The European Medicines Agency (EMA) gave the green light to
the AstraZeneca vaccine four days ago, saying there was not yet
enough results for people over the age of 55 to determine how
well the vaccine worked in that group but that it could still be
given to older people.

The approval is expected to ease pressure on the French
government, whose vaccination rollout strategy has been heavily
criticized for being too slow.

As of Feb. 1, more than 1.6 million doses had been
administered in France. That compares with an estimate of nearly
10 million in Britain.

But the European Union, which last year agreed to buy up to
400 million doses of the vaccine for the bloc, is at the centre
of a dispute with AstraZeneca over the speed of supplies.

Last week, the company unexpectedly announced cuts of up to
60% in supplies to European countries, citing production
problems at a Belgian factory and triggering a furious response
from Brussels.

The HAS said it expected France to get 10 million doses of
the AstraZeneca vaccine in the next three months, which would
allow 5 million people to get vaccinated, given its two-dose
regimen.

In the same timeframe, France hopes to secure 19.3 million
shots from Pfizer/BioNTech and 3 million from Moderna.

French European Affairs Minister Clement Beaune said on
Monday he expected first doses of the AstraZeneca vaccine to
arrive by next week at the latest.

(Reporting by Sudip Kar-Gupta, Geert De Clercq; Writing by
Matthias Blamont; Editing by Bernadette Baum and Rosalba
O'Brien)

More News
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.